<DOC>
	<DOCNO>NCT00631462</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability orally administer TG101348 patient myelofibrosis .</brief_summary>
	<brief_title>A Dose-escalation Study Safety Tolerability Orally Administered TG101348 Patients With Myelofibrosis</brief_title>
	<detailed_description>TG101348 potent small molecule inhibitor Janus kinase 2 ( JAK2 ) . This first-in-human study include dose-escalation phase , establish maximum tolerated dose , expand cohort , dose-confirmation phase . The safety , tolerability , pharmacokinetics , pharmacodynamics , preliminary clinical activity TG101348 patient myelofibrosis evaluate .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>Diagnosis myelofibrosis ( primary , postpolycythemia vera , postessential thrombocythemia ) At least 18 year age . ECOG PS 0 , 1 , 2 . Any chemotherapy , immunomodulatory therapy , immunosuppressive therapy , corticosteroid , growth factor treatment within 14 day prior initiation study drug . Major surgery radiation therapy within 28 day prior initiation study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>primary myelofibrosis</keyword>
	<keyword>post-polycythemia vera myelofibrosis</keyword>
	<keyword>post-essential thrombocythemia myelofibrosis</keyword>
</DOC>